Holen Sie sich die Stockscreener-App
1.32
5.60%
0.07
Vorhandelsmarkt:
1.32
Schlusskurs vom Vortag:
$1.25
Offen:
$1.26
24-Stunden-Volumen:
2.00M
Relative Volume:
0.60
Marktkapitalisierung:
$172.21M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.17M
KGV:
-1.7683
EPS:
-0.7465
Netto-Cashflow:
$-85.97M
1W Leistung:
+14.78%
1M Leistung:
+44.99%
6M Leistung:
+46.94%
1J Leistung:
+5.60%
1-Tages-Spanne:
$1.26
$1.35
1-Wochen-Bereich:
$1.07
$1.35
52-Wochen-Spanne:
$0.5062
$1.51
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
1.32 | 163.08M | 0 | -97.17M | -85.97M | -0.7465 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-07 | Eingeleitet | Roth Capital | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
IMUX SEC FilingsImmunic Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim initiates coverage of Immunic (IMUX) with buy recommendation - MSN
If You Invested $1,000 in Immunic Inc (IMUX) - Stock Titan
Immunic stock jumps after Guggenheim initiates with Buy By Investing.com - Investing.com Canada
Immunic (IMUX) Gains on Guggenheim's Buy Rating and Promising Dr - GuruFocus
Immunic stock jumps after Guggenheim initiates with Buy - Investing.com UK
Immunic stock gains new Buy at Guggenheim (IMUX:NASDAQ) - Seeking Alpha
Immunic (NASDAQ:IMUX) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
IMUX: Guggenheim Initiates Coverage with a Buy Rating and $7 Pri - GuruFocus
Immunic stock initiated at Buy by Guggenheim on MS therapy potential By Investing.com - Investing.com South Africa
Immunic, Inc. (NASDAQ:IMUX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Tangible book value per share of Immunic, Inc. – FWB:10VA - TradingView
Bull Bear: Does Immunic Inc meet Warren Buffetts criteria2026 Sector Moves & Expert-Curated Trade Recommendations - baoquankhu1.vn
US Stocks Recap: Will Immunic Inc stock recover after earningsFed Meeting & Weekly Return Optimization Alerts - baoquankhu1.vn
Immunic, Inc. (IMUX) announces European patent grant for vidofludimus calcium - MSN
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium - Insider Monkey
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next - MarketBeat
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug By Investing.com - Investing.com Canada
Immunic at Stifel CNS Forum: Strategic Insights on MS Drug - Investing.com
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference - MarketBeat
Immunic Inc Stock Operating Data - GuruFocus
Why did IMUX stock surge 33% pre-market today? - MSN
Short Interest in Immunic, Inc. (NASDAQ:IMUX) Rises By 14.5% - MarketBeat
Immunic Stock Under Pressure Amid Financial Changes and Market Reactions - StocksToTrade
Immunic Shares Rise Amid Resilient Strategy In Uncertain Markets - timothysykes.com
Immunic Inc. Faces Slow Recovery Amid Financial Struggles - StocksToTrade
symbol__ Stock Quote Price and Forecast - CNN
Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic’s (IMUX) Long-Term Value Proposition? - simplywall.st
New European patent covers all dosing regimens of experimental MS therapy - Multiple Sclerosis News Today
A Look At Immunic (IMUX) Valuation As Reverse Split Proposal And Conference Appearance Draw Attention - simplywall.st
Volume Recap: What makes Immunic Inc stock attractive today2026 Closing Moves & Consistent Return Investment Signals - baoquankhu1.vn
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug - Investing.com Australia
Immunic at Leerink Global Healthcare Conference: Strategic Insights on MS Drug By Investing.com - Investing.com India
Immunic secures European patent for vidofludimus calcium dosing By Investing.com - Investing.com Canada
Small cap wrap: Immunic, AtaiBeckley, Standard Uranium, Trust Stamp… - Proactive Investors
Immunic secures European patent for vidofludimus calcium dosing - Investing.com Nigeria
Immunic (IMUX) Secures Key European Patent for Vidofludimus Calc - GuruFocus
Biopharmaceutical company Immunic, Inc. announced that it has been granted a key European patent, which will provide important protection for the administration regimen related to Vidofludimus calcium. - Bitget
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium - PR Newswire
Immunic secures European patent for MS drug candidate vidofludimus calcium - Proactive financial news
What makes Immunic Inc. (10VA) stock appealing to growth investorsOil Prices & Real-Time Volume Surge Alerts - Naître et grandir
IMUX Forecast, Price Target & Analyst Ratings | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
IMUX Earnings History & Surprises | EPS & Revenue Results | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering - Stocktwits
Earnings Update: Whats the analyst consensus on Immunic IncDay Trade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
HC Wainwright Has Bearish Estimate for Immunic Q1 Earnings - MarketBeat
Deep Track group reports 11.45M-share stake in Immunic (IMUX) - Stock Titan
Immunic, Inc. Announces Participation in Investor Conferences Scheduled for March 2026 - geneonline.com
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):